Morgan Stanley Maintains Overweight on Boston Scientific, Raises Price Target to $100
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Patrick Wood maintains an Overweight rating on Boston Scientific and raises the price target from $92 to $100.
October 24, 2024 | 4:29 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Morgan Stanley has reaffirmed its Overweight rating on Boston Scientific and increased the price target from $92 to $100, indicating a positive outlook.
The increase in price target from $92 to $100 by Morgan Stanley suggests a positive outlook for Boston Scientific, likely boosting investor confidence and potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100